
Sartorius Stedim Biotech SA
PAR:DIM

Operating Margin
Sartorius Stedim Biotech SA
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
FR |
![]() |
Sartorius Stedim Biotech SA
PAR:DIM
|
17B EUR |
14%
|
|
US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
15%
|
|
US |
![]() |
Thermo Fisher Scientific Inc
NYSE:TMO
|
180.6B USD |
18%
|
|
US |
![]() |
Danaher Corp
NYSE:DHR
|
147.1B USD |
20%
|
|
KR |
![]() |
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
32%
|
|
CH |
![]() |
Lonza Group AG
SIX:LONN
|
39.6B CHF |
18%
|
|
US |
![]() |
IQVIA Holdings Inc
NYSE:IQV
|
34.7B USD |
15%
|
|
US |
![]() |
Agilent Technologies Inc
NYSE:A
|
34.1B USD |
23%
|
|
CN |
![]() |
WuXi AppTec Co Ltd
SSE:603259
|
256.7B CNY |
27%
|
|
US |
![]() |
Mettler-Toledo International Inc
NYSE:MTD
|
26.3B USD |
29%
|
|
IN |
![]() |
Divi's Laboratories Ltd
NSE:DIVISLAB
|
1.8T INR |
28%
|
Sartorius Stedim Biotech SA
Glance View
Sartorius Stedim Biotech SA has been weaving the intricate threads of biotechnology innovation into a fabric of global influence and success. Established as a pivotal player in the biopharmaceutical industry, Sartorius Stedim Biotech has carved out a niche by offering sophisticated products and solutions that cater to the unique needs of biopharmaceutical manufacturers. The company’s portfolio is a testament to the fusion of scientific ingenuity and relentless pursuit of quality. Spanning filtration and purification solutions, fermentation equipment, and fluid management systems, their offerings ensure that complex biological drugs, including vaccines and monoclonal antibodies, are produced efficiently and safely. Sartorius Stedim Biotech’s endeavor is not just about supplying equipment; it’s about providing integrated solutions that optimize the entire production process, ensuring consistency, scalability, and compliance in industries bound by strict regulatory oversight. The company generated revenue through its comprehensive range of products and services that address every step of the biomanufacturing process. Their business model hinges on fostering long-term relationships with clients by offering tailored solutions that enhance productivity and reduce time-to-market for new therapies. Beyond direct sales of high-value equipment, Sartorius Stedim Biotech also capitalizes on recurring revenue streams generated from consumables and maintenance services essential for the ongoing operation of their systems. By continuously innovating and expanding its product lines, the company stays at the forefront of technological advancements, enabling clients to tackle the ever-evolving challenges of bioproduction. As the global biopharmaceutical industry surges forward, driven by increasing demand for biologics, Sartorius Stedim Biotech remains poised to maintain its role as an indispensable ally to firms dedicated to transforming the health landscape through revolutionary therapies.

See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Sartorius Stedim Biotech SA's most recent financial statements, the company has Operating Margin of 14.1%.